Short answer
Aclaris Therapeutics, Inc. (ACRS) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1M (down 55.1% year over year) with net income of −$19M.
Q3 2026 key financials · XBRL
- Revenue
- $1M
- −55.1% YoY · −9.1% QoQ
- Net income
- −$19M
- −26.7% YoY · +13.9% QoQ
- Operating margin
- -1441.2%
- EPS (diluted)
- −$0.13
- −8.3% YoY · +13.3% QoQ
Source: XBRL data from the Aclaris Therapeutics, Inc. (ACRS) Q3 2026 10-Q on SEC EDGAR. USD.
Aclaris Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $1.481M, down $1.818M YoY from $3.299M, primarily lower licensing revenue
- Q3 net loss $18.510M vs $14.614M YoY, operating loss $21.344M vs $17.149M
- Strongest R&D growth: ATI-052 expense $5.906M, up $4.069M YoY; ATI-9494 $4.676M, up $3.272M
- Cash and securities $204.6M, including $20.4M cash and $184.2M marketable securities
- Nine-month operating cash use $62.076M vs $33.982M; management expects losses and additional capital needs near term
Risk Factors
- Liquidity risk: $204.6 million cash, cash equivalents and marketable securities against $59.8 million nine-month net loss
- Financing risk: October offering added $46.7 million net proceeds through 7,785,714 shares and 6,500,000 pre-funded warrants
- Marketable-securities concentration: $184.2 million fair value, including $70.5 million corporate debt securities maturing within one to three years
- Regulatory milestone exposure: $10.7 million contingent consideration tied to Confluence regulatory and commercial milestones
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aclaris Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.